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Purpose/Objective: To analyse the outcome of Carcinoma 
Cervix patients treated with CT based planning for both 
External beam treatment and Brachytherapy, with the 
objective of understanding the benefits afforded by image 
based optimised Brachytherapy. 
Materials and Methods: Data of 60 patients from among 509 
radically treated Cervix cancer patients treated with CT 
based treatment plans, between January 2011 to December 
2012 were analysed for outcome. In view of extreme number 
of patients and limited resources, treating every patient with 
conformal RT is far from reality at our centre. Hence after 
the instillation of CT simulator at our centre, conventional 
pelvic EBRT portals were planned on CT images, making field 
adjustments ensuring target coverage, on the basis of soft 
tissue imaging information. Subsequently on similar lines CT 
imaging was used for Brachytherapy planning and isodose 
shaping to cover the cervix and uterus while keeping the 
normal organ doses within normal limits was attempted. CT 
optimization in Brachytherapy was to reduce OAR doses if 
found excessive with standard planning and Point A dose 
prescription. Subsequently dose volume optimization was 
attempted. But where the central disease was of small 
volume the point A dose was still kept at the standard 
prescription range if the OAR doses were acceptable. 
Results: At a median follow up of 22 months (5-36mo), 9 
patients in the CT planned group documented relapse. 4 
patients had distant relapse and 5 had pelvic recurrence. Of 
the pelvic recurrences one patient recurred outside the 
initial treatment field (lower vaginal) and one patient 
documented progressive disease while on EBRT. The 3 other 
patients with true in-field recurrence had very advanced 
disease at presentation with bladder infiltration on imaging. 
Proper Brachytherapy application was not possible in 2 of 
these patients due to poor anatomy. There were no 
documented grade 2, 3 bladder toxicity. 6 patients had grade 
2 rectal toxicity. During the same period there were 32 
relapses and 16 isolated infield failures among the 258 CT 
planned patients treated with conventional 2D 
Brachytherapy. Also there were 22 grade 2 rectal toxicities in 
the patients treated with 2D brachytherapy. 
Conclusions: CT imaging information could be used for EBRT 
and Brachytherapy planning with excellent clinical outcome 
in a setting with large patient numbers and limited resources. 
Technology adaptation to suit our conditions is important for 
improving outcome of cervix cancer patients in the 
developing world. 
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Purpose/Objective: To evaluate the dosimetric impact of 
implementing inhomogeneity corrections for vaginal vault 
brachytherapy and assess for correlations with patient 
related factors. 
Materials and Methods: The plans of 48 consecutive patients 
treated with post-operative HDR vaginal vault brachytherapy 
using a single line source were evaluated. All patients had a 
planning CT scan with the vaginal cylinder in situ. The PTV 
consisted of the cranial 4 cm of vagina to a depth of 5mm, 
and any gas in the bowel was outlined over a standard 
number of CT slices and the volume measured and the 
diameter of the equivalent sphere estimated. The point doses 
for 3 randomly placed points in the PTV were measured and 
compared for a plan assuming a homogeneous tissue density 
equivalent to water (1g/cm3)with another plan using Acuros ™ 
correction for tissue inhomogeneities. The 2-sample T-test 
for unequal variances (t) and the Pearson's correlation 
coefficient (r) with 2-tail significance testing at level of ≤ 
0.05 were used to evaluate the differences and study the 
correlations between the 2 plans and patient related factors 
of: volume of gas in bowel, age, vaginal length and cylinder 
diameter. The differences in dwell times between the 2 plans 
were used to generate 2 subgroups: the 1st quartile and the 
4th quartile. 
Results: For the 48 patients in the study the median age: 67 
yrs(22 - 82 yrs), and post-operative vaginal length: 11cm (8 -
13cm). The cylinder diameters used: 17% had 2.6cm, 19% had 
3cm and 64% had 3.5cm. The median volume of gas: 9.58cm3 
(0.08 – 115.4cm3) and the diameter for the equivalent 
sphere: 2.6cm (0.5 – 6cm). The Acuros correction resulted in 
a median increase in dwell times of 2.35%(2.0 – 3.52%).The 
percentage increase in dwell times correlated with the 
volume of gas (r=0.815; p=0.0000072) and the diameter of 
equivalent sphere (r=0.783;p=0.000037) but not with the 
vaginal length or cylinder diameter. On comparison of the 2 
subgroups there were significant differences in volume of air 
(t=1.76;p=0.0013) and sphere diameter (t=1.72; p=0.00008) 
but not in vaginal length or cylinder diameter. 
Conclusions: The use of inhomogeneity correction for vaginal 
vault brachytherapy will reflect more accurately the 
dosimetry at the time of the scan. It is significantly 
influenced by the volume of gas in the bowel which may not 
be constant throughout a fractionated course of treatment. 
Further studies on reproducibility are required. 
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Purpose/Objective: To analyze the long term results of daily 
high dose-rate brachytherapy (HDRBT) in vaginal-cuff 
relapses (VCR) and toxicity in postoperative endometrial 
carcinoma (EC). 
Materials and Methods: From January 2007 to September 
2011, 153 patients with FIGO Stage 38-IA, 69-IB, 16-II, 13-IIIA, 
2-IIIB, 10-IIIC1 and 5-IIIC2, were treated with HDRBT after 
surgery. Pathology: 136 /153 endometrioid adenocarcinoma 
and 17/153 other types. Radiotherapy: Group 1: 94/153 
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External beam irradiation (mean 45 Gy, range 44-50.4)+ 
HDRBT (2 fractions of 5-6 Gy); Group 2: 59/153 HDRBT alone 
(4 fractions of 5-6 Gy). Chemotherapy: 26 patients (4 cycles 
of carboplatin+paclitaxel). Toxicity evaluation: RTOG scores 
for bladder and rectum and the objective criteria of LENT-
SOMA for vagina. Statistics: Chi-square and Fisher exact tests.  
Results: Mean age (years): Group 1: 65 (40-88); Group 2: 62 
(39-90). Mean follow-up (months): Group 1: 47.51 (8.64-
82.149); Group 2: 48.08 (11.99-96.66). VCR: Only 2 patients 
in Group 1 (2.12%) and no patients in group 2(0%). Toxicity: 
Early problems in Group 1 appeared in 5.3 % in rectum (G1-
2), 7.5% in bladder (G1-2) and 2.1% in vagina (G1); late 
problems appeared in 7.3 % in rectum (all G1-2 but 1 G3), 
1.1% in bladder (G1) and 27.7% in vagina (all G1-2 but 1 G4). 
Group 2: Early: 6.7% in bladder (G1-2), 6.6% in vagina (G1-2). 
Late toxicity: Only vaginal problems were observed in 21.7% 
(G1-2). Significant differences were only found in rectal 
toxicity between Group 1 and Group 2 (p=0.004). 
Conclusions: The present brachytherapy schedule for 
postoperative treatment of EC of 2 fractions of 5 Gy after EBI 
and 4 fractions of 5 Gy administered on a daily basis is a safe 
regime in terms of local control and toxicity. Similar results 
were found in a previous series with an increased number of 
fractions.  
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Purpose/Objective: In our Gynaecological Cancer Centre in 
Zagreb, Croatia, we treat annually with radical irradiation 
around 100 patients with cervical cancer. We start with 
chemo-irradiation (TD 45Gy/25fr with weekly Cisplatin 
40mg/m2), and afterwards we continue with high dose rate 
(HDR) intracavitary brachytherapy (Iridium 192 source, 
Flexitron afterloading machine). We usually prescribe 4x7Gy 
to point A, and for many years we did Manchester planning 
based on X ray images with dose restrictions to organs at risk 
(OR) according to ICRU (International Commission on 
Radiation Units) 38 recommendations. After attending two 
gynaecological GEC ESTRO courses in 3D brachytherapy and 
an ESTRO funded visit to Department of Brachytherapy at the 
Institute of Oncology Ljubljana, our objective was to 
introduce 3D brachytherapy practice to our Centre. We 
realized that our main challenge was imaging since we have 
CT simulator and no MRI at our Centre. After learning the 
principles of GTV (gross tumour volume) and HR CTV (high 
risk clinical target volume) contouring on MR images, we 
tried to implement them to CT images. What helped greatly 
was our own clinical practice of trans-vaginal ultrasound (TV 
US) measurements of cervical tumour before and after 
chemo-irradiation.  
Materials and Methods: To evaluate advantages of 3D 
brachytherapy planning over Manchester planning we did a 
pilot study on 10 patients with cervical cancer. After they 
received chemo-irradiation we performed our usual 
brachytherapy application with Rotterdam applicator 
(intrauterine tandem + ovoids). For each patient we obtained 
CT images and contoured HR CTV based on US measurements 
and gynaecological (GYN) GEC ESTRO working group 
recommendations. TV US offered width, height and thickness 
of the cervical tumour. 
 
 
 
For each patient we did Manchester plan and 3D plan with 
dose prescription to point A or D90 HR CTV (minimum dose 
delivered to 90% of the respective volume) accordingly. 
Planning was done on Nucletron’s Oncentra planning system. 
Dose restrictions to OR were according to ICRU points in 
rectum and bladder for Manchester planning and 2cc GEC 
ESTRO recommendations for rectum, bladder and sigma for 
3D brachytherapy planning.  
Results: With 3D planning we were able to increase 
prescription dose to D90 HR CTV, (especially in large 
tumours), while respecting restriction doses to OR. Unlike 
Manchester plan, we could also provide better protection of 
sigma. With Manchester planning, small tumour volumes had 
large doses in D90 HR CTV, but large tumour volumes were 
not as covered as in 3D planning. 
 
 
 
Conclusions: 3D brachytherapy planning offers better control 
of tumour coverage and protection of OR. The lack of MR 
image planning shouldn’t be an obstacle for the introduction 
